Summit Therapeutics' Ivonescimab Shows PFS Benefit in NSCLC Trial
Event summary
- Summit Therapeutics published Phase III HARMONi trial results in The Lancet Oncology, showing ivonescimab plus chemotherapy improved PFS in EGFR-mutated NSCLC patients.
- Median PFS was 6.8 months for ivonescimab vs. 4.4 months for placebo (HR 0.52, p<0.0001).
- FDA set PDUFA date for ivonescimab BLA to November 14, 2026.
- Updated OS analysis to be presented at WCLC 2026 shows positive trend but not statistically significant.
- Ivonescimab is being evaluated in 16 Phase III trials across multiple cancer types.
The big picture
Summit Therapeutics' positive Phase III data for ivonescimab represents a potential new treatment option for EGFR-mutated NSCLC patients who have progressed on third-generation EGFR TKIs. The dual-targeting mechanism of ivonescimab (PD-1 and VEGF) differentiates it from traditional anti-PD-(L)1 therapies, which have shown limited benefit in this patient population. With over 16 Phase III trials ongoing, Summit is aggressively expanding ivonescimab's potential across multiple cancer types, positioning it as a key player in the oncology space.
What we're watching
- Regulatory Pathway
- Whether the FDA will approve ivonescimab by the November 2026 PDUFA date based on the current data.
- Commercial Strategy
- How Summit will position ivonescimab in the competitive NSCLC treatment landscape.
- Clinical Development
- The pace at which additional Phase III trial results for ivonescimab will be read out across different cancer indications.
Related topics